Continuous Glucose Monitor (CGM): At-Home and Finger-Prick Options, Normal Ranges, and What the Data Say

What Exactly Does a CGM Measure, and Why Does It Matter?

A CGM sensor threads a tiny filament into the subcutaneous tissue and reads interstitial glucose electrochemically every 1 to 5 minutes. The result is a continuous trace rather than a snapshot. That trace reveals spikes, crashes, overnight patterns, and meal responses that a quarterly HbA1c or a single fasting glucose simply cannot show.

A fasting glucose of 95 mg/dL looks reassuring, but the same person might spike to 175 mg/dL after breakfast and stay there for 90 minutes before returning to baseline. That pattern is associated with higher cardiovascular risk even when standard lab panels appear normal. A 2020 analysis in the Journal of the American College of Cardiology (N=7,656) found that 1-hour postprandial glucose >155 mg/dL predicted incident diabetes and cardiovascular events independent of fasting glucose.

The Interstitial Lag

Interstitial glucose lags capillary blood glucose by approximately 5 to 15 minutes during rapid glucose changes. Most modern CGMs apply a proprietary algorithm to correct for this, but the lag is worth knowing when interpreting a sharp post-meal rise or a fast-acting hypoglycemia event. During stable glucose periods, agreement between CGM and finger-prick is excellent, with mean absolute relative differences (MARD) below 9% for current-generation devices. FDA device labeling for the Dexcom G7 lists a MARD of 8.2% against venous reference.

Why Variability Is as Important as the Average

Two people can share the same 7-day mean glucose of 100 mg/dL while having completely different risk profiles. One spends most hours near 100 mg/dL. The other oscillates between 65 and 155 mg/dL repeatedly. High glycemic variability drives oxidative stress, advanced glycation end-product (AGE) formation, and endothelial dysfunction through the same pathways as sustained hyperglycemia. The ADA-endorsed metric for variability is coefficient of variation (CV), calculated as (standard deviation ÷ mean) × 100. The 2017 International Consensus on Time in Range defined CV <36% as the threshold for "stable" glucose in people with diabetes, a benchmark now widely adopted in longevity medicine for non-diabetic adults as well.

At-Home CGM Device Options: What Is Available Right Now

The sensor market has expanded significantly since 2017. Three devices now dominate home use in the United States.

Abbott FreeStyle Libre 3

The Libre 3 uses a 14-day sensor worn on the back of the upper arm. It transmits readings automatically every minute via Bluetooth to a smartphone app, eliminating the need to wave the phone over the sensor as earlier Libre models required. Accuracy (MARD) is reported at 7.9% in Abbott's key trial data. The key accuracy study for the Libre 3 was submitted to the FDA and published supporting data in Diabetes Technology and Therapeutics showing MARD of 7.8 to 7.9% across all glucose ranges.

The Libre 3 Plus (cleared in 2024) extends wear to 15 days and integrates with automated insulin delivery systems. For non-diabetic users interested in metabolic tracking, the standard Libre 3 requires a prescription in the U.S. But is available over the counter in several European countries.

Dexcom G7

The Dexcom G7 features a 10-day sensor with a 30-minute warm-up period, down from the 2-hour warm-up of the G6. It has a separate transmitter built into the sensor pod, making it the smallest Dexcom device to date. MARD is 8.2% per FDA labeling. The G7 integrates with iOS and Android, Apple Watch, and major insulin pumps.

Dexcom's Stelo, cleared by the FDA in 2024 as the first over-the-counter CGM in the U.S. For adults without insulin-treated diabetes, uses the G7 platform and costs approximately $99 for a two-sensor pack. FDA's 510(k) clearance of Stelo (K231516) noted it is indicated for adults 18 and older not on insulin.

Abbott Lingo

Lingo launched in 2024 as a direct-to-consumer metabolic health CGM, marketed to non-diabetic adults interested in nutrition optimization. It uses the same underlying sensor technology as the Libre platform and does not require a prescription. The app focuses on "glucose scores" and personalized food insights rather than clinical alerts.

Finger-Prick Glucometers: Still Useful, Still Accurate

A finger-prick reading uses capillary blood drawn from a fingertip and measured on a test strip in a handheld meter in under 5 seconds. FDA-cleared meters must meet ISO 15197:2013 accuracy requirements, meaning 95% of readings must fall within ±15 mg/dL of a reference lab value for glucose <100 mg/dL and within ±15% for glucose >100 mg/dL.

When Finger-Prick Still Makes Sense

• Confirming a CGM alarm before acting (hypoglycemia below 70 mg/dL warrants a capillary check if symptoms do not match the sensor reading)
• Spot-checking during the CGM sensor warm-up window
• Traveling internationally where CGM supplies are difficult to obtain
• Cost-sensitive situations (test strips for a basic meter cost roughly $0.20 to 0.50 each versus $35 to 65 per CGM sensor)

Popular Meter Options

The Contour Next One (MARD ~4.7% in post-market studies) and the OneTouch Verio Reflect consistently rank among the most accurate consumer meters in published accuracy comparisons in the Journal of Diabetes Science and Technology. Both connect to smartphones via Bluetooth.

Finger-prick testing two to four times daily provides a rough trend but misses postprandial excursions between checks and gives no overnight data. A person checking at 7 am and noon can have a "normal" log while experiencing sustained 160 mg/dL readings every night.

CGM Normal Range and Optimal Targets: The Evidence Base

"Normal" depends on clinical context. The ADA uses one target set for diagnosed diabetes management; longevity-focused clinicians use a tighter set for metabolic optimization.

ADA Time-in-Range Consensus Targets (2023)

The 2023 ADA Standards of Care define the following TIR targets for people with type 1 or type 2 diabetes: American Diabetes Association, Standards of Care in Diabetes 2023, Section 6.

| Glucose Zone | Range (mg/dL) | Target (% of Day) | |---|---|---| | Time in range (TIR) | 70 to 180 | >70% | | Time below range (TBR) Level 1 | 54 to 69 | <4% | | Time below range (TBR) Level 2 | <54 | <1% | | Time above range (TAR) Level 1 | 181 to 250 | <25% | | Time above range (TAR) Level 2 | >250 | <5% |

For older or high-risk individuals, the ADA relaxes TIR to >50%.

Tighter Targets for Non-Diabetic Metabolic Optimization

Longevity-focused clinicians and researchers such as Peter Attia and teams at the Institute for Functional Medicine have proposed a stricter target range for non-diabetic adults: 70 to 140 mg/dL for >90% of the day, with mean glucose between 89 and 104 mg/dL. These targets are not codified in a single society guideline but derive from the continuous-glucose profiles observed in truly healthy, lean, insulin-sensitive reference populations.

A 2019 study in PLOS Biology (N=57 healthy adults without diabetes) found mean CGM glucose of 99 ± 7 mg/dL, with 96% TIR at 70 to 140 mg/dL, establishing a real-world reference for non-diabetic CGM profiles.

Peak postprandial glucose in that cohort exceeded 140 mg/dL in 15% of readings and exceeded 160 mg/dL in 2% of readings, even in healthy participants, which underscores that brief excursions after large carbohydrate loads are common even in people with optimal metabolic health.

Fasting and Overnight Glucose

Overnight readings (midnight to 6 am) reflect hepatic glucose output and cortisol dynamics. Target overnight glucose is 70 to 100 mg/dL. Persistent overnight readings above 110 mg/dL without a corresponding evening carbohydrate load may indicate early insulin resistance or elevated cortisol, and warrant investigation. Readings below 65 mg/dL during sleep may indicate reactive hypoglycemia from a late-evening meal or, in people on insulin or sulfonylureas, nocturnal hypoglycemia requiring medication review.

Glycemic Variability Metrics Your CGM Report Generates

Most CGM apps and companion platforms (LibreView, Dexcom Clarity, Levels, January AI) generate a standard AGP (Ambulatory Glucose Profile) report after at least 14 days of data. The key metrics are:

Mean Glucose and GMI

The glucose management indicator (GMI) is estimated HbA1c derived from mean CGM glucose using the formula: GMI (%) = 3.31 + 0.02392 × mean glucose (mg/dL). The GMI equation was validated in a multicenter study published in Diabetes Care, 2018 (N=528 CGM users). GMI correlates with laboratory HbA1c but may differ by up to 0.5 percentage points in individuals with hemoglobin variants or conditions affecting red blood cell turnover.

Coefficient of Variation (CV%)

CV% = (SD ÷ mean glucose) × 100. A CV below 36% indicates stable glycemia. Values above 36% signal wide swings that may require dietary, lifestyle, or medication changes regardless of mean glucose.

Standard Deviation (SD)

SD targets for non-diabetic optimization are below 18 mg/dL. An SD above 25 mg/dL with a mean glucose of 95 mg/dL is a more concerning profile than an SD of 12 mg/dL with a mean of 108 mg/dL.

Factors That Drive Glucose Spikes on a CGM

Understanding what moves glucose upward helps interpret the CGM trace meaningfully rather than just panicking at every excursion.

Diet Composition

Refined carbohydrates spike glucose faster than the same caloric load from protein or fat. White rice produces a higher and faster spike than brown rice in head-to-head comparisons. A 2015 randomized crossover study in the American Journal of Clinical Nutrition (N=11) found white rice produced a 2-hour glucose AUC 26% higher than an isocaloric portion of parboiled rice. Combining carbohydrates with fiber, fat, or protein consistently blunts the peak and extends the return to baseline.

Exercise

Aerobic exercise during or immediately after a meal dramatically reduces post-meal spikes. A 10-minute walk within 30 minutes of eating reduces the postprandial glucose peak by approximately 20 to 30% compared to remaining sedentary. A 2022 meta-analysis in Sports Medicine (22 trials, N=1,036) confirmed that post-meal walking reduced 2-hour postprandial glucose by a mean of 21.4 mg/dL versus sitting controls.

Resistance exercise may cause a transient glucose rise from catecholamine and cortisol release before the subsequent insulin-sensitizing effect lowers glucose over the following 24 to 48 hours.

Sleep Quality

Poor sleep (less than 6 hours or fragmented sleep) raises fasting glucose by 10 to 20 mg/dL the following morning through cortisol and growth hormone dysregulation. Wearers often see this pattern clearly on a CGM after a bad night, which can be motivating for behavior change in a way that a quarterly HbA1c never is.

Stress and Illness

Psychological stress raises glucose through the HPA axis. Acute illness, particularly with fever, can spike glucose by 30 to 60 mg/dL even in non-diabetic individuals due to counter-regulatory hormone surges.

Medications

Several common medications raise glucose on CGM. Prednisone at 40 mg/day can raise fasting glucose by 40 to 80 mg/dL and cause pronounced postprandial spikes. Thiazide diuretics, atypical antipsychotics (olanzapine, quetiapine), and high-dose niacin all shift the CGM trace upward. Conversely, GLP-1 receptor agonists (semaglutide, tirzepatide) flatten postprandial spikes within the first few weeks of use, a change that is visible on CGM before any change in HbA1c becomes detectable.

Who Should Wear a CGM Outside of Diagnosed Diabetes?

The evidence base is strongest for three non-diabetic groups:

Prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%): CGM frequently reveals that fasting glucose alone underestimates glucose burden. The CDC estimates 96 million U.S. Adults have prediabetes, and 80% are unaware. CGM in prediabetes can identify the subset with severe postprandial excursions who are most likely to progress and who benefit most from targeted intervention.

Polycystic Ovary Syndrome (PCOS): Insulin resistance affects up to 70% of women with PCOS regardless of body weight. A review in the Journal of Clinical Endocrinology and Metabolism noted that up to 70% of PCOS patients demonstrate insulin resistance on dynamic testing even when fasting glucose is normal. CGM gives a real-world picture of insulin resistance that static lab tests miss.

GLP-1 and Metabolic Therapy Monitoring: Patients starting semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can track the drug's glycemic effect directly. The Dexcom Stelo was partly designed for this population.

The HealthRX clinical team uses a three-tier framework to guide CGM use in non-diabetic patients:

• Tier 1 (Screening, 14 days): One sensor worn after a standard fasting metabolic panel to identify unrecognized postprandial hyperglycemia or high CV. No ongoing monitoring needed if all metrics are optimal.
• Tier 2 (Intervention tracking, 30 to 90 days): Continuous wear during a dietary change, GLP-1 initiation, or exercise program to provide real-time feedback and guide titration.
• Tier 3 (Chronic monitoring): Ongoing CGM for patients with prediabetes, PCOS with insulin resistance, or HbA1c trending above 5.5% despite lifestyle efforts.

Prescription vs. Over-the-Counter: What You Can Get Without a Doctor

As of 2024, two CGM products are available without a prescription in the U.S.:

• Dexcom Stelo: Cleared for adults 18+ not using insulin. $99 per pack of two sensors (20 days total). Available at CVS, Walgreens, and Amazon.
• Abbott Lingo: Direct-to-consumer subscription model, approximately $49 to 89 per month depending on plan. Not FDA-cleared as a medical device for diabetes management but cleared as a general wellness device.

All other CGM sensors (Libre 3, Dexcom G7, Dexcom G6) require a prescription in the U.S. Telehealth platforms, including HealthRX, can provide a prescription-grade sensor with a clinician-reviewed CGM report as part of a metabolic workup.

Finger-prick meters and test strips require no prescription and are available at any pharmacy.

Interpreting Your First Two Weeks of CGM Data: A Practical Checklist

Reading a CGM report for the first time can feel overwhelming. Focus on these five numbers in order:

1. Mean glucose: Is it between 89 and 104 mg/dL?
2. CV%: Is it below 36%?
3. TIR at 70 to 140 mg/dL: Is it above 90%?
4. Peak postprandial excursions: Does glucose exceed 160 mg/dL after any meal? If so, which meals?
5. Overnight nadir: Does glucose drop below 65 mg/dL at any point during sleep?

If mean glucose exceeds 110 mg/dL, CV exceeds 40%, or postprandial peaks consistently exceed 160 mg/dL, those findings warrant a clinical conversation rather than self-adjustment alone.

The 2021 International Consensus on TIR from Diabetes Care states: "TIR should be included in the standard metrics for clinical management and clinical trials, as it provides complementary information to HbA1c."

Limitations and Caveats

CGM is a strong tool but not a perfect one. Acetaminophen (Tylenol) can falsely raise readings on older CGM platforms, though the Libre 3 and Dexcom G7 have substantially reduced this interference. Sensor compression at night (lying on the sensor) causes artifactual drops. Altitude and low perfusion states can reduce accuracy.

CGM does not measure insulin levels directly. A person can have perfectly normal glucose while running very high insulin levels to maintain it, a compensated insulin-resistant state that only insulin or HOMA-IR testing would reveal. CGM glucose data and fasting insulin should be interpreted together for a full metabolic picture.

Finally, CGM data requires context. A single spike to 155 mg/dL after a birthday cake is not a clinical problem. A pattern of 10 spikes above 155 mg/dL per day, every day, with a CV of 45% and a mean of 112 mg/dL is worth addressing.